Surgical Outcomes in Gastric Cancer

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

“Quality of surgery can make the most tremendous difference to your chances of survival and the quality of a patient’s remaining life,” said Professor van de Velde. “In rectal cancer, for example, the local recurrence rate can vary enormously between surgeons, from 5% to 50% or 60%, and this can affect not only your risk of dying of metastases, but the degree of suffering. Many local recurrences in rectal cancer are untreatable and cause immense and unbearable symptoms.”

“Survival rates in gastric and rectal cancer can vary as much as 5% to 10% between different surgeons, more than the effect gained from adjuvant treatment.” Professor van de Velde continued. “Morbidity, mortality and survival vary substantially between surgeons. Also more extensive surgery does not necessarily improve survival, so addressing the issues about individual surgical performance is a major issue.” 

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Related Content